Kurz Katrin S, Kalmbach Sabrina, Ott Michaela, Staiger Annette M, Ott German, Horn Heike
Department of Clinical Pathology, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany.
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, University of Tübingen, 70376 Stuttgart, Germany.
Cancers (Basel). 2023 Jan 27;15(3):785. doi: 10.3390/cancers15030785.
The conceptual description of Follicular lymphoma (FL) in the 5th edition of the World Health Organization (WHO) classification of haematolymphoid tumors (WHO-HAEM5) has undergone significant revision. The vast majority of FL (85%) with a follicular growth pattern are composed of centrocytes and centroblasts, harbor the t(14;18)(q32;q21) translocation and are now termed classic FL (cFL). They are set apart from three related subtypes, FL with predominantly follicular growth pattern, FL with unusual cytological features (uFL) and follicular large B-cell lymphoma (FLBCL). In contrast to the revised 4th edition of the WHO classification of haematolymphoid tumors (WHO-HAEM4R), grading of cFL is no longer mandatory. FL with a predominantly diffuse growth pattern had been previously recognized in WHO-HAEM4R. It frequently occurs as a large tumor in the inguinal region and is associated with CD23 expression. An absence of the fusion and frequent mutations along with 1p36 deletion or mutation is typical. The newly introduced subtype of uFL includes two subsets that significantly diverge from cFL: one with "blastoid" and one with "large centrocyte" variant cytological features. uFL more frequently displays variant immunophenotypic and genotypic features. FLBCL is largely identical to WHO-HAEM4R FL grade 3B and renaming was done for reasons of consistency throughout the classification. In-situ follicular B-cell neoplasm, pediatric-type FL, duodenal-type FL and primary cutaneous follicle center lymphoma are categorized as discrete entities. In addition, novel findings concerning underlying biological mechanisms in the pathogenesis of early and systemic follicular lymphoma will be presented.
世界卫生组织(WHO)血液淋巴系统肿瘤分类(WHO-HAEM5)第5版中对滤泡性淋巴瘤(FL)的概念描述有了重大修订。绝大多数具有滤泡生长模式的FL(85%)由中心细胞和中心母细胞组成,存在t(14;18)(q32;q21)易位,现被称为经典型FL(cFL)。它们与三种相关亚型区分开来,即主要为滤泡生长模式的FL、具有异常细胞学特征的FL(uFL)和滤泡性大B细胞淋巴瘤(FLBCL)。与WHO血液淋巴系统肿瘤分类第4版修订版(WHO-HAEM4R)不同,cFL的分级不再是必需的。主要为弥漫生长模式的FL在WHO-HAEM4R中已被认识到。它常表现为腹股沟区的大肿瘤,与CD23表达相关。典型表现为无 融合以及频繁的 突变,同时伴有1p36缺失或 突变。新引入的uFL亚型包括两个与cFL有显著差异的亚组:一个具有“母细胞样”特征,另一个具有“大中心细胞”变异细胞学特征。uFL更常表现出变异的免疫表型和基因型特征。FLBCL在很大程度上与WHO-HAEM4R中的FL 3B级相同,为了在整个分类中保持一致而进行了重新命名。原位滤泡B细胞肿瘤、儿童型FL、十二指肠型FL和原发性皮肤滤泡中心淋巴瘤被归类为不同的实体。此外,还将介绍早期及系统性滤泡性淋巴瘤发病机制中潜在生物学机制的新发现。